Dr. Boro Dropulić’s @NatureMedicine World View article describes the high costs of CAR-T and other cellular gene therapies. He explains how point-of-care manufacturing and technology transfer can improve access to these life-saving treatments.
https://www.nature.com/articles/s41591-024-03231-z
#GeneTherapy
Join our Deputy ED Research & Clinical Services - Dr. Francis Ssali as a keynote speaker at the 3rd Sickle Cell Disease Convention in Jinja this Friday, July 5th, 2024. Gain valuable insights & knowledge from a leading expert in the field. Don't miss this exceptional opportunity!
An honor indeed!!
As the genetic medicines field celebrates 2 approved medicines (+1 on the way) for SCD, on this #SickleCellDisease day - this image of our world matters the most. It shows the global prevalence of this devastating disease and the #HealthJustice challenge before all of us.
How do we take the shining example of Emily Whitehead, cured of her pediatric cancer, and scale it?
Dr. Crystal Mackall @MackallLab, Dr Donald Kohn @Kohn_Lab, and a team of fellow SMEs across all facets of the problem space offer an actionable path.
#PlatformCures
#HealthJustice
Join the CMC Vellore campus centenary celebrations from affar. You can watch back the Centenary Celebrations Thanksgiving Service on the @OffCMCVellore YouTube channel here:
It helps us understand duration of anti-CD38 mAb. 2 years of maintenance reduced death or progression by 24% WHEN the anti-CD38 was used in induction-consolidation. This is the first time any drug proves on a clean design to impact PFS in maintenance in the setting of QUADs. 5/X
Today, the @OSUCCC_James Cell Therapy Laboratory and @OSUHematology teams are celebrating a big milestone of over 500 patients treated with non-BMT #celltherapy products like CAR T cells, NKs, TILs, and more! Our team is incredible! And all for the patients! ♥️🩶
